Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 9/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 8/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 8/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.33 |
| ▸ | GRIK4 | Q16099 | 3/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL1528037 | 1.00 | SLC7A5 (0.35) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL27580772 | 1.00 | SLC7A5 (0.35) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL14940945 | 0.95 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL183769 | 0.95 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL183768 | 0.95 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL2024731 | 0.92 | SLC7A5 (0.37) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL27673557 | 0.90 | GRIA1 (0.40) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL27610893 | 0.89 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 | |
| Histidine SCHEMBL5670665 | 0.89 | SLC7A5 (0.34) | SLC7A5CYP1A2GRIA4GRIA1GRIA2 | |
| Histidine SCHEMBL6947397 | 0.89 | SLC7A5 (0.37) | SLC7A5CYP3A4CYP1A2GRIA4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263550-B2 | Exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110071076-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7858740-B2 | Exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070010656-A1 | Novel exendin agonist compounds | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071076-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | GLP1R, GIPR, GPR119 | SLC7A5 570/4885CYP3A4 3301/4885CYP1A2 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.